Intriguing RNAi company spawned by the EMBL & Max Plank Institute, currently recruiting...
cenix-bioscience.com
...Integrating nearly 4 years of intensive R&D devoted exclusively to the field of RNAi, CENIX is the first and only company in the world to offer fully operational RNAi-based drug development programmes for both conventional and RNAi-based therapeutics.
CENIX’s long-term mission is therefore to establish itself as the premiere RNAi-based therapeutics company, exploiting its pioneering expertise using RNAi in multiple experimental systems to develop its own pipeline of conventional small molecule drugs and the exciting new class of RNAi-based medicines. CENIX will initially focus its internal therapeutics development programmes on key, high priority oncology indications, before expanding them to a wider, carefully selected range of disease fields...
CENIX’s three scientific founders, Drs. Echeverri, Hyman and Gönczy, were among the first to recognise the potential of RNAi in early 1998. By combining its power with the first fully sequenced animal genome, that of the nematode worm Caenorhabditis elegans, they sought to achieve for the first time a systematic and truly comprehensive genome-wide analysis of gene function. The system’s proof of concept was established through the detailed RNAi-based phenotypic analysis of one entire C. elegans chromosome (~2,200 genes), which generated in vivo function data for nearly 300 genes in a matter of months (Nature 408:331, Nov. 2000).
Thus, while most in the industry have only recently begun to explore this technology, CENIX has capitalised on its 4 year lead by further developing its founders’ prototypic screening system to create a fast-growing arsenal of mature and versatile RNAi-based technology platforms optimised for therapeutic drug development. In order to maximise the scope of applicability of these technologies, CENIX is exploiting several complementary experimental systems, including C. elegans, Drosophila, cultured human cells, as well as normal and disease animal models, starting with mice in Q2/2002.... |
